Understanding of Zaire ebolavirus–human protein interaction for drug repurposing
Tóm tắt
The Ebola virus is a human aggressive pathogen causes Ebola virus disease that threatens public health, for which there is no Food Drug Administration approved medication. Drug repurposing is an alternative method to find the novel indications of known drugs to treat the disease effectively at low cost. The present work focused on understanding the host–virus interaction as well as host virus drug interaction to identify the disease pathways and host-directed drug targets. Thus, existing direct physical Ebola–human protein–protein interaction (PPI) was collected from various publicly available databases and also literature through manual curation. Further, the functional and pathway enrichment analysis for the proteins were performed using database for annotation, visualization, and integrated discovery and the enriched gene ontology biological process terms includes chromatin assembly or disassembly, nucleosome organization, nucleosome assembly. Also, the enriched Kyoto Encyclopedia of Genes and Genome pathway terms includes systemic lupus erythematosus, alcoholism, and viral carcinogenesis. From the PPI network, important large histone clusters and tubulin were observed. Further, the host–virus and host–virus–drug interaction network has been generated and found that 182 drugs are associated with 45 host genes. The obtained drugs and their interacting targets could be considered for Ebola treatment.
Tài liệu tham khảo
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-into decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091–3.
Bixler SL, Duplantier AJ, Bavari S. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017;9:299–317. https://doi.org/10.1007/s40506-017-0130-z.
Bradley JH, Harrison A, Corey A, Gentry N, Gregg RK. Ebola virus secreted glycoprotein decreases the anti-viral immunity of macrophages in early inflammatory responses. Cell Immunol. 2018;324:24–32. https://doi.org/10.1016/j.cellimm.2017.11.009.
Calderone A, Licata L, Cesareni G. VirusMentha: a new resource for virus–host protein interactions. Nucleic Acids Res. 2015;43:D588–92.
Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli L, et al. MINT: the molecular INTeraction database. Nucleic Acids Res. 2007;35:2006–8.
Chatr-Aryamontri A, Oughtred R, Boucher L, Rust J, Chang C, Kolas NK, et al. The BioGRID interaction database: 2017 update. Nucleic Acids Res. 2017;45:D369–79.
Cheng AC, Kelly H. Are we prepared for Ebola and other viral haemorrhagic fevers? Aust N Z J Public Health. 2014;38:403–4.
Cotto KC, Wagner AH, Feng Y, Kiwala S, Coffman C, Spies G, et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database. Nucleic Acids Res. 2018;46:1068–73.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane H, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:R60. https://doi.org/10.1186/gb-2003-4-9-r60.
Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.
Douer D. Efficacy and safety of vincristine sulfate liposome injection in the treatment of adult acute lymphocytic leukemia. Oncologist. 2016;21:840–7.
Dube D, Schornberg KL, Shoemaker CJ, Delos SE, Stantchev TS, Clouse KA, et al. Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci. 2010;107:16637–42. https://doi.org/10.1073/pnas.1008509107.
Dyary HO, Rahman HS, Othman HH, Abdullah R, Chartrand MS. Advancements in the therapy of Ebola virus disease. Pediatr Infect Dis Open Access. 2016;01:1–6.
García-Dorival I, Wu W, Dowall S, Armstrong S, Touzelet O, Wastling J, et al. Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host–cell protein function. J Proteome Res. 2014;13:5120–35.
Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. Cancer therapy: clinical a phase i study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009;15:4207–13.
Guirimand T, Delmotte S, Navratil V. VirHostNet 2.0: surfing on the web of virus/host molecular interactions data. Nucleic Acids Res. 2015;43:D583–7.
Hermjakob H. IntAct: an open source molecular interaction database. Nucleic Acids Res. 2004;32:D452–5. https://doi.org/10.1093/nar/gkh052.
Kamal A, Suresh P, Ramaiah MJ, Mallareddy A, Ashwini B, Raju P, et al. Bioorganic and medicinal chemistry synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents. Bioorg Med Chem. 2011;19:4589–600. https://doi.org/10.1016/j.bmc.2011.06.017.
Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:109–14.
Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17:35–56. https://doi.org/10.1038/nrd.2017.162.
Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, Chen C, et al. The IntAct molecular interaction database in 2012. Nucleic Acids Res. 2012;40:D841–6.
Khanderao A, Sankunny J, Karuppayil M. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b. In Silico Pharmacol. 2017;5:1–12.
Knipe DM, Lieberman PM, Jung JU, Mcbride AA, Morris KV, Ott M, et al. Snapshots: chromatin control of viral infection. Virology. 2014;435:141–56.
Kouznetsova J, Sun W, Martínez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, García-Sastre A. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3:1–6.
Lieberman PM. Chromatin organization and virus gene expression. J Cell Physiol. 2008;216:295–302.
Liu L, Wei J, Ruan J. Pathway enrichment analysis with networks. Genes (Basel). 2017;8:1–12.
Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS ONE. 2013;8:e60579.
Mahanty S, Bray M. Reviews pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004;4:487–98.
Mohapatra S, Saha A, Mondal P, Jana B, Ghosh S. Synergistic anticancer effect of peptide-docetaxel nanoassembly targeted to tubulin: toward development of dual warhead containing nanomedicine. Adv Healthc Mater. 2017;6:1600718.
Moss ML, Palmer RE, Kuzmih P, Dunlap BE, Henzelq W, Kofron JL, et al. Identification of actin and HSP 70 as cyclosporin A binding proteins assays. J Biol Chem. 1992;267:22054–9.
Murayama M, Tsujimoto K, Uozaki M, Katsuyama Y, Yamasaki H, Utsunomiya H, et al. Effect of caffeine on the multiplication of DNA and RNA viruses. Med Rep. 2008;68:251–5.
Newcomb WW, Brown JC. Internal catalase protects herpes simplex virus from inactivation by hydrogen peroxide. J Virol. 2012;86:11931–4. https://doi.org/10.1128/JVI.01349-12.
Oliveros JC. VENNY. An interactive tool for comparing lists with Venn Diagrams. 2007. http://bioinfogp.cnb.csic.es/tools/venny/index.html.
Peri S. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2003;32:D497–501.
Ruthel G, Demmin GL, Kallstrom G, Javid MP, Badie SS, Will AB, et al. Association of Ebola virus matrix protein VP40 with microtubules. J Virol. 2005;79:4709–19. https://doi.org/10.1128/JVI.79.8.4709-4719.2005.
Sanderson CM, Hollinshead M, Smith GL. The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J Gen Virol. 2000;81:47–58.
Schmidt N, Gans EH. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol. 2011;4:22–9.
Schuler J. A systematic review of computational drug discovery, development, and repurposing for Ebola virus disease treatment. Molecules. 2017;22:1777.
Shannon P, Markiel A, Owen O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
Sordet O, Goldman A, Pommier Y. Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes. Mol Cancer Ther. 2006;5:3139–45.
Suryanarayana K, Baczko K, Volker M, Wagner RR. Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue. J Virol. 1994;68:1532–43.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52.
Takada A, Kawaoka Y. The pathogenesis of Ebola hemorrhagic fever. Trends Microbiol. 2001;9:506–11.
Tavassoli A. Targeting the protein–protein interactions of the HIV lifecycle. Chem Soc Rev. 2011;40:1337–46.
Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of Ebola virus matrix protein VP40. Virology. 2001;283:1–6.
Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, et al. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol. 2007;84:119–29.
Wang C, Ravelli RBG, Roussi F, Steinmetz MO, Knossow M, Curmi PA. Structural basis for the regulation of tubulin by vinblastine. Nat Lett. 2005;435:519–22.
Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–81.
Zhao Y. Towards structural based drug development for Ebola virus disease. J Chem Biol Ther. 2016;1:1–3.